551 results match your criteria: "Institute for Cancer Research and Treatment[Affiliation]"
Clin Genitourin Cancer
August 2018
Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Electronic address:
Background: The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population.
Methods: Data were collected across 24 Italian centers.
Lancet
January 2018
Academic Unit of Medical Oncology, San Martino Polyclinic Hospital-Institute for Cancer Research and Treatment, 16132 Genoa, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.
Ther Adv Med Oncol
January 2018
Academic Unit of Medical Oncology, San Martino Polyclinic Hospital, Institute for Cancer Research and Treatment, L.go R. Benzi 10, 16132, Genoa, Italy.
Background: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials, and their association with survival outcomes.
Methods: This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- post-docetaxel).
J Clin Oncol
March 2018
Michael J. Overman and Scott Kopetz, University of Texas MD Anderson Cancer Center, Houston, TX; Sara Lonardi, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padova; Fabio Gelsomino, University Hospital of Modena, Modena; Massimo Aglietta, Institute for Cancer Research and Treatment of Candiolo, University of Torino Medical School, Turin, Italy; Ka Yeung Mark Wong, Sydney Medical School, University of Sydney, Sydney, New South Wales; Andrew Hill, Tasman Oncology Research, Ltd., Southport, Queensland, Australia; Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Michael A. Morse, Duke University Medical Center, Durham, NC; Eric Van Cutsem, University Hospitals Gasthuisberg Leuven and Katholieke Universiteit Leuven, Leuven; Alain Hendlisz, Institut Jules Bordet; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels; Jean-Marie Ledeine, Bristol-Myers Squibb, Braine-L'Alleud, Belgium; Ray McDermott, St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland; Michael B. Sawyer, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada; Magali Svrcek and Thierry André, Hopital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, Université Pierre et Marie Curie, Paris, France; and Rebecca A. Moss, Z. Alexander Cao, and Shital Kamble, Bristol-Myers Squibb, Princeton, NJ.
Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes.
View Article and Find Full Text PDFOncotarget
October 2017
Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), University of Paris Est, ERL-CNRS 9215, 94010 Créteil, France.
In this study, a novel anticancer reagent based on polyplexes nanoparticles was developed. These nanoparticles are obtained by mixing negatively charged polyelectrolytes with the antitumour cationically-charged pseudopeptide N6L. Using two experimental tumor pancreatic models based upon PANC-1 and mPDAC cells, we found that the antitumour activity of N6L is significantly raised its incorporation in polyplexed nanoparticles.
View Article and Find Full Text PDFOncologist
December 2017
Department of Oncology, University and General Hospital, Udine, Italy
Background: Second-line therapy has consistently demonstrated survival benefit if compared with best supportive care; however, there is limited evidence whether further lines of treatment may improve the prognosis of advanced gastric cancer (AGC) patients.
Materials And Methods: Starting from a real-world cohort of 868 AGC patients, we retrospectively analyzed baseline parameters, tumor characteristics, and treatment data of those treated with at least three lines. Categorical features were described through cross-tables and chi-square test.
J Am Soc Echocardiogr
November 2017
DEI, University of Bologna, Cesena, Italy. Electronic address:
Background: Cardiotoxicity is a well-known adverse effect of various chemotherapeutic agents that can be monitored by echocardiography. A decrease in left ventricular ejection fraction (LVEF) triggers consideration for therapy modification or interruption. The aim of this study was to evaluate how variability in LVEF estimates computed using three-dimensional echocardiography could influence cardiotoxicity onset detection.
View Article and Find Full Text PDFPathol Oncol Res
July 2018
Department of Diagnostics and Public Health, AOUI, University of Verona, Verona, Italy.
The new WHO 2016 classification of renal neoplasia encounters the new entity called "clear cell papillary renal cell carcinoma" (ccpRCC). The ccpRCC has been long included as a subtype of clear cell RCC histotype and it actually ranges from 2 to 9% in different routinely available cohort of renal carcinomas. Of important note, ccpRCC does not show any recurrences or metastases or lymph-node invasion and the outcome is always good.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
May 2017
Institute of Experimental Neurology (INSpe) (S.S., M.D.D., A.R., R.M., E.B., M. Romeo, F.S., G.D.C., M. Rodegher, M. Radaelli, L.M., G.M., R.F., V.M., G.C., C.F.), Division of Neuroscience, San Raffaele Scientific Institute, Milan; University Vita-Salute San Raffaele (S.S., E.B., G.C.), Milan; and Laboratory of Functional Genomics (D.C., E.M.), Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Candiolo, Italy.
Endocr Relat Cancer
February 2017
Department of Biomedical and Neuromotor SciencesSection of Anatomic Pathology 'M. Malpighi' at Bellaria Hospital, University of Bologna, Bologna, Italy
Hobnail variant of papillary thyroid carcinoma (HPTC) represents a recently described, aggressive and rare group of thyroid tumors with poorly understood pathogenesis. Molecular data about this group of cancers are few, and a more detailed molecular characterization of these tumors is needed. The main objective of the study is to define a comprehensive molecular typing of HPTC.
View Article and Find Full Text PDFClin Oral Investig
September 2017
Nuclear Medicine Unit, San Luigi Gonzaga University Hospital, Orbassano, Italy.
Objective: The aim of this study was the assessment of semi-quantified salivary gland dynamic scintigraphy (SGdS) parameters independently and in an integrated way in order to predict primary Sjögren's syndrome (pSS).
Materials And Methods: Forty-six consecutive patients (41 females; age 61 ± 11 years) with sicca syndrome were studied by SGdS after injection of 200 MBq of pertechnetate. In sixteen patients, pSS was diagnosed, according to American-European Consensus Group criteria (AECGc).
Gastric Cancer
September 2017
Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.
Background: Although second-line therapy is often considered for advanced gastric cancer patients, the optimal candidates are not well defined.
Methods: We retrospectively collected baseline parameters, tumour features, and treatment data for 868 advanced gastric cancer patients exposed to multiple treatment lines at 19 Italian centres. Cross-tables and chi-square tests were used to describe categorical features.
Am J Hematol
November 2016
Hematology Unit Department of Onco-Hematology, a.O. Of Cosenza, Cosenza, Italy.
The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients.
View Article and Find Full Text PDFRadiol Med
November 2016
Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi, 30, 20097, San Donato Milanese, Milan, Italy.
Women who underwent chest radiation therapy (CRT) during pediatric/young-adult age (typically, lymphoma survivors) have an increased breast cancer risk, in particular for high doses. The cumulative incidence from 40 to 45 years of age is 13-20 %, similar to that of BRCA mutation carriers for whom contrast-enhanced magnetic resonance imaging (MRI) is recommended. However, in women who underwent CRT, MRI sensitivity is lower (63-80 %) and that of mammography higher (67-70 %) than those observed in women with hereditary predisposition, due to a higher incidence of ductal carcinoma in situ with microcalcifications and low neoangiogenesis.
View Article and Find Full Text PDFOncotarget
July 2016
CeRMS, A.O. Città della Salute e della Scienza, Torino, Italy.
Cancer stem cells (CSCs) are key players in bone metastasis. In some renal tumors CSCs overexpress the HGF receptor c-MET, speculating that c-MET targeting could lead to bone metastasis inhibition. To address this hypothesis we isolated renal CD105+/CD24-CSCs, expressing c-MET receptor from a primary renal carcinoma.
View Article and Find Full Text PDFInt J Urol
September 2016
Division of Radiology, Institute for Cancer Research and Treatment, Turin, Italy.
Objectives: To evaluate the role of multiparametric magnetic resonance imaging in improving the predictive accuracy of the Prostate Cancer Research International: Active Surveillance and Epstein criteria for active surveillance in prostate cancer.
Methods: A retrospective study was carried out with 126 prostate cancer patients treated with robot-assisted radical prostatectomy, but eligible for active surveillance according to the Prostate Cancer Research International: Active Surveillance criteria; 63 patients were also eligible according to the Epstein criteria. All patients underwent preoperative multiparametric magnetic resonance imaging, after at least 6 weeks from biopsy.
Appl Clin Genet
June 2016
Cardiothoracovascular Department, Marfan Syndrome and Related Disorders Regional Referral Center, Careggi Hospital, Florence, Italy; Cardiology Service, CMSR Veneto Medica, Altavilla Vicentina, Italy.
Marfan syndrome (MFS) is a pleiotropic connective tissue disease inherited as an autosomal dominant trait, due to mutations in the FBN1 gene encoding fibrillin 1. It is an important protein of the extracellular matrix that contributes to the final structure of a microfibril. Few cases displaying an autosomal recessive transmission are reported in the world.
View Article and Find Full Text PDFFront Pharmacol
May 2016
Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto Taranto, Italy.
Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evaluate the role of early PSA decline for detection of therapy success or failure in mCRPC patients treated with AA in post chemotherapy setting.
Patients And Methods: We retrospectively evaluated 87 patients with mCRPC treated with AA.
Sarcoma
March 2016
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola, 80131 Napoli, Italy.
Background. In several prospective and retrospective studies, weekly paclitaxel showed promising activity in patients with angiosarcoma. Patients and Methods.
View Article and Find Full Text PDFInt J Mol Sci
February 2016
Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge 14183, Sweden.
The selective estrogen receptor (ER) modulator tamoxifen (TAM) has become the standard therapy for the treatment of ER+ breast cancer patients. Despite the obvious benefits of TAM, a proportion of patients acquire resistance to treatment, and this is a significant clinical problem. Consequently, the identification of possible mechanisms involved in TAM-resistance should help the development of new therapeutic targets.
View Article and Find Full Text PDFJ Nucl Cardiol
June 2017
Unit of Nuclear Medicine and Department of Cardiology, S. Maugeri Foundation, IRCCS, Veruno, Italy.
J Nucl Cardiol
June 2017
Department of Health Sciences, University of Milan and Nuclear Medicine Unit, San Paolo Hospital, Milan, Italy.
Background: The purpose of this study was to evaluate the image quality in cardiac F-FDG PET using the time of flight (TOF) and/or point spread function (PSF) modeling in the iterative reconstruction (IR).
Methods: Three scanners and an anthropomorphic cardiac phantom with an insert simulating a transmural defect (TD) were used. Two sets of scans (with/without TD) were acquired, and four reconstruction schemes were considered: (1) IR; (2) IR + PSF, (3) IR + TOF, and (4) IR + TOF + PSF.
Br J Haematol
December 2016
Haematology-Oncology Department, Azienda Ospedaliera Cosenza, Cosenza, Italy.
BMC Cancer
December 2015
Department of Medical Sciences, University of Turin, Via Santena 7, 10126, Turin, Italy.
Background: The incidence of meningeal carcinomatosis appears to be higher than in the past due to advances in neuro-imaging diagnostic techniques and improvements in cancer survival. Among solid tumors, breast cancer is the cancer most commonly associated with meningeal carcinomatosis, with an incidence rate of between 0.8 and 16%.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
December 2015
Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Pisa, Italy.
Background: After progression to a standard first-line platinum and gemcitabine combination (GP), there is no established second-line therapy for patients with advanced biliary tract cancers (aBTC). Indeed, literature data suggest limited activity of most second-line agents evaluated so far.
Methods: We collected a large retrospective series of aBTC patients treated with second-line chemotherapy after progression to a first-line GP regimen at different Italian institutions.